My PCR Releases New Resource on Treatment Free Remission (TFR)

My PCR Releases New Resource on Treatment Free Remission (TFR)

My PCR has released a new FAQ about Treatment Free Remission (TFR) – a potential treatment goal for some patients living with chronic myeloid leukemia (CML).

To keep patients at the center of our process, the Max team asked patient leaders and associations from around the world to send in their own questions about TFR. We compiled their submissions, identified common themes, and narrowed the field down to 10 key questions.

Download the My PCR Treatment-Free Remission FAQ (PDF)

The answers in the FAQ were provided by CML expert, Max Medical Advisor, and friend of the organization, Dr. Michael J. Mauro of Memorial Sloan Kettering Cancer Center. Thanks to his extensive knowledge and experience, the document offers valuable information for patients and providers alike.

This FAQ marks another new resource created by The Max Foundation’s My PCR initiative – a global effort to increase access to polymerase chain reaction (PCR) testing for CML.

The Max Foundation extends its thanks to all the generous sponsors who make the My PCR initiative possible:

  • Major Sponors: Bristol-Myers Squibb, Pfizer, Novartis, and Takeda Oncology
  • Supporting Sponsors: Asuragen, Cepheid, and Incyte

With their support we’re expanding access to critical diagnostics in low- and middle-income countries around the world.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries

    The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries

    IPIG joins Max’s Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) and will provide medical education and training on PNH care and management Max will provide access to innovative treatment as part of the multi-stakeholder collaboration focused on eradicating survival disparities in 53 low-resource countries People living with this rare blood disease require frequent….

  • The Max Foundation’s 2019 Annual Report is Now Live

    The Max Foundation’s 2019 Annual Report is Now Live

    “Looking back at 2019 a common theme stands out: reaching new frontiers,” write The Max Foundation CEO Pat Garcia-Gonzalez and The Max Foundation Board President Paula Boultbee in the report.

  • Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award

    Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award

    The Max Foundation is proud to announce that our Chief Executive Officer Pat Garcia-Gonzalez has been named a finalist for the Union for International Cancer Control (UICC)’s CEO Award!